Xenetic Biosciences Inc (XBIO.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|51||2017||Chief Executive Officer, Chief Operating Officer, Director|
|52||2017||Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer|
|56||2017||Chief Scientific Officer|
|69||2017||Treasurer, Secretary, Director|
- BRIEF-Xenetic Biosciences qtrly loss per share $0.26
- BRIEF-Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
- BRIEF-Xenetic Biosciences appoints Jeffrey Eisenberg as CEO
- BRIEF-XENETIC BIOSCIENCES PROVIDES UPDATE ON ANNUAL MEETING OF STOCKHOLDERS
- BRIEF-Xenetic Biosciences says its annual stockholder meeting scheduled for Aug 16 was convened and dismissed